# Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

> **NCT00079092** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 18 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** procarbazine hydrochloride
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00079092
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-01
- **Primary completion:** 2006-03-21
- **Final completion:** 2006-03-21
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2021-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079092, "Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00079092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*